Oncology

The Middle East healthcare giant posts record profits and a $163M dividend, fueled by aggressive international acquisitions and a major bet on AI technology.

A 15-year pharma alliance expands to Austria, bringing advanced relief to cancer patients suffering from chemotherapy's debilitating side effects.

Median Technologies' eyonis® LCS gains landmark FDA clearance, promising to revolutionize early detection of the deadliest cancer with its AI-powered diagnostics.

Australian biotech Immutep reaches a key milestone in its Phase III trial for a novel lung cancer therapy, a major step in a multi-billion dollar market.

EMD Serono and the Trump Administration launch a new program offering massive discounts on IVF drugs, bringing hope to millions of aspiring parents.

As HUTCHMED prepares to unveil its 2025 financials, investors weigh a complex picture of global drug success, domestic pressures, and pipeline promise.

Kelun-Biotech's sac-TMT gains its fourth approval in China, doubling survival time for patients with advanced HR+/HER2- breast cancer.

A new cancer drug using DNA fragments to deliver chemotherapy more safely has been cleared for US trials, offering hope for less toxic treatments.

Manipal's new comprehensive cancer centre in South Bengaluru integrates robotic surgery, precision radiation, and holistic support to combat rising cancer rates.

Akeso's innovative dual-action antibody secures its fifth breakthrough nod, offering a lifeline for patients with advanced biliary tract cancer.

Ascentage Pharma's next-gen BTK degrader, APG-3288, receives dual IND clearance, paving the way for clinical trials to fight resistant blood cancers.

Stunning real-world data shows Iovance's Amtagvi is more effective in earlier melanoma treatment, potentially changing clinical practice and offering new hope.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.

New data reveals Orca-T cell therapy boosts survival and cuts complications in blood cancer, as the company prepares for a potential FDA approval this year.

TransCode Therapeutics and Quantum Leap are targeting hidden cancer cells with a novel RNA drug in a pivotal trial that could prevent colorectal cancer relapse.

For the third consecutive year, Virginia Cancer Specialists has been named the top practice in Virginia. We explore how they achieved this sustained success.

Empyrean Medical Systems partners with Wide Code to bring its advanced MOVHEET radiation therapy to Greater China, a strategic move in a booming oncology market.

Despite product withdrawals, a lack of regulation and the long latency of asbestos-related diseases mean the danger from talc exposure is far from over.

A new study reveals Exicure's burixafor mobilizes stem cells in one hour, promising to streamline cancer treatment and unlock future gene therapies.